3rd AMERICA DRUG SAFETY & AI 2025

World’s greatest minds in drug safety, pharmacovigilance, data analysis, reporting, government policy, and innovative technology united under the Why Summits Future of Pharmacovigilance World Tour

key information

What to expect

  • A Narrative Approach: This conference unfolds as a compelling story, showcasing personal experiences from exceptional professionals in Drug Safety and Pharmacovigilance, united by their mission to deliver safe medicines and improve global health.
  • Timely Industry Insights: Gain expert perspectives on current challenges, from integrating disruptive technologies into rigid PV processes to managing priorities under tightening budgets, advancing methodologies for new therapies, and evolving signal detection strategies.
  • Future-Focused Workforce: Explore how to build winning cross-functional teams, leverage the strengths of millennials, Gen Z, and industry veterans, and address the workforce needs of a forward-looking drug safety department.
  • Comprehensive Topics: Engage in discussions on end-to-end PV Operations including Innovations, Evolving regulations, Harmonization, Optimizing Risk Management strategies, AI and Automation, Advanced Adverse Event Management, Patient Involvement, all with the shared mission of faster, safer, and sustainable patient care.
  • Dynamic Networking Opportunities: Participate in visionary keynotes, best practice case studies, panel discussions, and both formal and informal networking sessions designed to foster meaningful partnerships and innovative solutions.

Main takeaways

BENEFITS OF ATTENDING

  • Forward-Looking Insights: Discover the latest trends, challenges, and advancements in pharmacovigilance from world-renowned industry leaders. Prepare for the future of drug safety with actionable strategies.
  • Unparalleled Networking: Build connections with senior executives, regulatory specialists, and industry pioneers. Expand your professional network and collaborate with like-minded experts to drive innovation.
  • Comprehensive Engagement: Participate in interactive discussions and hands-on sessions tackling key issues like emerging technologies, regulatory changes, and operational excellence, all led by top professionals.
  • Global Expertise: Gain a worldwide perspective on the pharmacovigilance landscape, with insights into international regulations, diverse market environments, and strategies for effective global collaboration.
  • Knowledge Exchange: Share experiences, learn best practices, and explore cutting-edge solutions to enhance your organization’s safety and compliance frameworks.

Target audience breakdown:

Summit Aligned with the 7 I's:

  • Intelligence: Insights from senior stakeholders with expertise in drug safety
  • Ideas: Exploring emerging trends and opportunities
  • Interaction: Benchmarking the best strategies in the industry
  • Inspiration: Discovering new approaches and how to leverage them
  • Innovation: Enhancing the effectiveness of PV organizations
  • Implementation: Turning plans into impactful actions
  • Improvement: Striving for excellence in pharmacovigilance

Elevate Your PV Game:
Mastering the 5 W’s

Who, What, When, Where, and Why are the cornerstones of effective process management and continuous improvement. Asking the right questions leads to meaningful answers—enabling you to set up processes with precision and drive greater effectiveness.

At our summit, dive into HOW to turn these foundational elements into actionable strategies that deliver measurable results. Learn. Innovate. Lead.

Past Event Speakers

Sean Green

Director, Safety Database Strategy and Analytics

Apellis Pharmaceuticals

Christine Hunter

Senior Consultant, Veeva Safety

Veeva Systems

Abdul Rahim

CEO & Founder

Alwis Solutions

Jamie Wilkins

Head- Risk Management Center of Excellence - Worldwide Safety

Pfizer

Nina Patel Lahanis

VP, Safety Data Management

PrimeVigilance

Jacqueline Gerena

Director Risk Management Strategy

Johnson & Johnson

Katarina Ilic

Expert Consultant

Mina Ebeid

Director Drug Safety and Pharmacovigilance Scientist

Genmab US, Inc

Robert Huber, PhD

Co-founder and Chief Product Officer

Veridat

Manjiri Nirgudkar

Director, Global Risk Management

BMS

Past Event Partners

Industry Pioneers Attending From

Testimonials

5/5
Excited to have participated in the American Drug Safety Summit in Boston, MA! 🌟 It was an honor to highlight the successful partnerships and collaborations between our Safety and Social teams over the past couple of years as well as connect and learn from with industry Subject Matter Experts. A key takeaway for me: AI is coming/ AI is now- How can we utilize this tool, not only to bring efficiencies into our work, but also focus on value-add and increasing quality of work? Thank you to Alison Purdon for your sponsorship and mentorship over the past several years and inviting me to join in on this opportunity! Thank you to Lubos K.and the #WhySummits team for all of your partnership and efforts creating a memorable event!
Marissa StLouis
Safety Partnering Lead, Genentech
5/5
I heard great things about the event from those who attended, and those who didn't manage to attend this year regret.
Katarina Ilic
Expert Consultant, Drug Safety, Clinical Pharmacology, Clinical Development, Pharmacoepidemiology
5/5
The American Drug Safety Summit 2025 was a great event to learn from industry experts about the evolution of patient safety. It was very interesting to see how AI is being leveraged in data-intensive projects to improve patient outcomes. The introduction to the REMS Industry Consortium was a highlight, and their work is truly inspiring.
Apoorva Anil Joshi
Senior Pharmacovigilance Product Scientist, Genentech
5/5
Attending this year American Drug Safety Summit 2025 in Boston by Why Summits was an absolute discovery for me. Attendees were not numerous but they represented top-notch leaders from pharma industry in the EU and USA. Discussions were so exciting and constructive - I enjoyed every moment of it. I am truly grateful to Jan, Lubos and Zuzana for such a smart planning of this important event.
Maja Barac
Director, EU Qualified Person for PV, PharmaVigil
5/5
I thoroughly enjoyed the interactive and spontaneous discussions on key pharmacovigilance topics, ranging from Gen AI to PV regulatory frameworks. The conference brought together a focused group of PV professionals, providing ample opportunities to connect and network with like-minded individuals. Overall, it was a successful conference and met its objectives.
Karthik Babu
Consumer Healthcare Global PV Operations Head, Sanofi
5/5
I want to express my gratitude to Lubos and the Why Summits team for a well-organized and informative Pharmacovigilance event. The comprehensive agenda, featuring a variety of expert presenters and engaging panel discussions, provided valuable insights and fostered productive networking. I'm eager to participate in future Why Summits events.
Israel Bocanegra
Associate Director, Business Development, Pharmacovigilance Technology Solutions

Everything you need to know about this event in one spot.

Check out our event overview and agenda and discover this conference.

REGISTRATION

Conference

Ticket | December 9-10, 2025
$ 2349
  • Access to All Conference Sessions of the 3rd America Drug Safety & AI 2025
  • Access to Post Conference Networking
  • Conference Materials
  • Includes Coffee Breaks, Snacks and Refreshments, Seated Lunch

BECOME A PARTNER

OF this EVENT
  • Present on the Main Stage
  • Hold an exhibit at this event
  • Showcase your Brand in Marketing Material
  • Gain exposure through alternative partnership benefits

Past Event partners

Gold Partner

PrimeVigilance, an Ergomed Group company, was established in 2008 by Dr. Miroslav Reljanovic together with co-founder Dr. Elliot Brown. PrimeVigilance offers holistic, top quality, cost-effective, innovative clinical safety and PV services for pharmaceutical, biotechnology and medical device companies. Our leaders have an unrivalled reputation in the sector with a network of SMEs across the world. These include former senior regulators and consultants with expansive industry experience.

Gold Partner

At Alwis Group, we’re pioneering AI-driven solutions for the healthcare and pharmaceutical industries. Our innovative tools are transforming pharmacovigilance, enhancing drug safety monitoring, and streamlining regulatory compliance. Our suite of products includes:

* ReTrans Enterprise: AI-powered literature surveillance

* ReTrans Extension: Browser plugin for real-time safety data analysis

* ScoMed: Intelligent medical literature scoring * ZiNex: Advanced medical document processing

* ZiQuel: AI-driven quality complaint management

* ZiTrack: Smart inbound receipt management

We’re committed to improving patient safety and operational efficiency through cutting-edge technology. Our solutions reduce costs, minimize errors, and accelerate processes, allowing healthcare professionals to focus on what matters most – patient care.

Silver Partner

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries.

Silver Partner

4C Pharma Solutions is a comprehensive global healthcare solutions company specializing in end to end of Pharmacovigilance, Materiovigilance, Medical Information Call Center, Hosting, Regulatory Affairs, Medical Affairs, CDM & Staff Augmentation.

Silver Partner

Quark empowers the world’s largest pharmaceutical companies to automate the production of their highly regulated or complex documentation, so they can approve and publish it faster, and stay compliant. It enables them to accelerate regulatory approvals, release the bottlenecks around content collaboration, and get their drugs to market in record time.

Quark Publishing Platform (QPP) NextGen, the cloud-based, AI-powered component content management system (CCMS) with native XML-based structured authoring using Microsoft Word, helps pharmacovigilance teams centralize and simplify the processes involved in co-authoring and approving the PV system’s critical drug safety documentation. This starts with the master file (PSMF) and traverses through all aggregated and regulatory affairs reports, including development safety update reports (DSURs), periodic adverse drug experience reports (PADERs), periodic safety update reports (PSURs), periodic benefit-risk evaluation reports (PBRERs) and risk management plans (RMPs).

Powered by Microsoft Azure OpenAI and connected with wider content and business software ecosystems such as Veeva and ArisGlobal, QPP NextGen manages every stage of the authoring and review lifecycle from end to end. PV teams increase productivity and save time by easily writing, importing, formatting and publishing complex types of variable global content to omnichannel submission outputs using structured, XML component-based authoring workflows, stringently tracking workflows in real time, driving risk reduction and safeguarding compliance.

Silver Partner

Biologit MLM-AI is a state-of-the-art platform for monitoring scientific literature to identify adverse events and emerging risks throughout a product’s lifecycle, from clinical development to post-marketing. Designed for teams of all sizes, it combines a flexible workflow with a unified global and local scientific database, enhanced by unique AI-driven screening and productivity tools. These features enable fast, accurate, and fully traceable results for all safety surveillance needs.

Biologit Database is a robust, continuously updated repository of scientific literature, optimised for compliant regulatory searches. It integrates global and regional sources into an intuitive interface, delivering high-quality results for monitoring adverse events and potential risks. With over 65 million entries and 40,000 new articles added daily from 120,000 journals across 170+ countries, it ensures comprehensive coverage aligned with FDA, EMA GVP and global standards.

 

Silver Partner

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. 

Veeva Safety applications operate as a unified pharmacovigilance system on a single cloud platform to maximize operational efficiencies and improve patient safety. Automating data flow and simplifying PV processes, Veeva Safety delivers solutions to manage case processing from intake to submissions, PSMF, pharmacovigilance agreements, RMPs, aRMMS, and more. For more information, visit veeva.com/safety.

Strategic Partner

Veridat brings together a range of capabilities to help clients in response to a changing environment, reduce risk in response to growing complexity, and improve the processes and systems that protect brands, build trust, and add business value. Our flagship product, Bench™, is a lightweight, flexible, and easily implemented rendering data immutable and verifiable.

Registered participants will be offered a free trial of 5,000 transactions to create their own environment and experience, to be able to test & verify the increased effectiveness of data management value chain.

Panel Partner

Advity Research is a quality-driven Contract Research Organization (CRO) based in Hyderabad, India; led by experienced technocrats:

  • Having extensive experience in the CRO industry
  • Possess commendable expertise
  • Committed to strengthening systems and teams while offering innovative approaches

With over 3 decades of experience in the CRO industry, Advity Research provides an integrated clinical research portfolio, which includes Bioavailability/Bioequivalence (BA/BE) services, clinical trial services, and pharmacovigilance services.

Pharmacovigilance Services:

We have consolidated our collective experience to provide comprehensive pharmacovigilance services. Our offerings include an experienced team, robust quality systems and processes, and a clear understanding of global pharmacovigilance requirements.

Currently, supporting Pharma & Biotech companies with products marketed across diverse geographic locations including the USA, UK, EU, Australia, and Canada. Our solutions cover:

  • Medical information call centre
  • Literature search
  • Database
  • Signal Management
  • Case processing to Aggregate reporting.
Read More

Agenda Download

Submission Successful!

Thank you for your interest! The agenda has been sent to your email. Click the button below if you want to open the agenda in a new tab.